Table 1.
Characteristics of enrolled studies.
| References | Study design | Year | Recruitment period | Location | Age | Sample size Ara:non-Ara | Intervention Ara:non-Ara | Dosage of Ara | Cycles of Ara | Outcome indicators |
|---|---|---|---|---|---|---|---|---|---|---|
| (6) | RCT | 2018 | 2012–2015 | China | 14–69 | 25:24 | MTX+Ara-C+WBRT:FTD+WBRT | 1 mg/m2 | 4 | CR, ORR, PFS, OS |
| (10) | RCT | 2015 | 2007–2010 | France | >60 | 47:48 | MTX+Ara-C+PV:MTX+TMZ | 3 mg/m2 | 3 | CR, ORR, PFS, OS |
| (4) | RCT | 2009 | 2004–2007 | Argentina, Greece, Italy, Peru, Portugal, Switzerland | 18–75 | 39:40 | MTX+Ara-C+WBRT:MTX+WBRT | 2 mg/m2 | 4 | CR, ORR, FFS, OS |
Ara, treatment with cytarabine; non-Ara, treatment without cytarabine; RCT, randomized clinical trial; MTX, methotrexate; Ara-C, cytarabine; WBRT, whole-brain radiotherapy; FTD, fotemustine, teniposide, and dexamethasone; PV, procarbazine and vincristine; CR, complete remission; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; FFS, failure-free survival.